David M Charytan1, Robert Padera2, Alexander M Helfand3, Michael Zeisberg4, Xingbo Xu5, Xiaopeng Liu5, Jonathan Himmelfarb6, Angeles Cinelli3, Raghu Kalluri7, Elisabeth M Zeisberg8. 1. Renal Division, Department of Medicine, Brigham & Women's Hospital, Boston, MA, United States. Electronic address: dcharytan@partners.org. 2. Department of Pathology, Brigham & Women's Hospital, Boston, MA, United States. 3. Renal Division, Department of Medicine, Brigham & Women's Hospital, Boston, MA, United States. 4. Department of Nephrology and Rheumatology, Georg-August University, Göttingen, Germany. 5. Department of Cardiology and Pneumology, University Medical Center, Georg-August University, Göttingen, Germany. 6. Department of Medicine, University of Washington School of Medicine, MD Anderson Cancer Center, Houston, TX, United States. 7. Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX, United States. 8. Department of Cardiology and Pneumology, University Medical Center, Georg-August University, Göttingen, Germany; DZHK (German Centre for Cardiovascular Research), partner site Göttingen, Germany.
Abstract
BACKGROUND: Sudden cardiovascular death is increased in chronic kidney disease (CKD). Experimental CKD models suggest that angiogenesis and nitric oxide (NO) inhibitors induce myocardial fibrosis and microvascular dropout thereby facilitating arrhythmogenesis. We undertook this study to characterize associations of CKD with human myocardial pathology, NO-related circulating angiogenesis inhibitors, and endothelial cell behavior. METHODS: We compared heart (n=54) and serum (n=162) samples from individuals with and without CKD, and assessed effects of serum on human coronary artery endothelial cells (HCAECs) in vitro. Left ventricular fibrosis and capillary density were quantified in post-mortem samples. Endothelial to mesenchymal transition (EndMT) was assessed by immunostaining of post-mortem samples and RNA expression in heart tissue obtained during cardiac surgery. Circulating asymmetric dimethylarginine (ADMA), endostatin (END), angiopoietin-2 (ANG), and thrombospondin-2 (TSP) were measured, and the effect of these factors and of subject serum on proliferation, apoptosis, and EndMT of HCAEC was analyzed. RESULTS: Cardiac fibrosis increased 12% and 77% in stage 3-4 CKD and ESRD and microvascular density decreased 12% and 16% vs. preserved renal function. EndMT-derived fibroblast proportion was 17% higher in stage 3-4 CKD and ESRD (P trend = 0.02). ADMA, ANG, TSP, and END concentrations increased in CKD. Both individual factors and CKD serum increased HCAEC apoptosis (P=0.02), decreased proliferation (P=0.03), and induced EndMT. CONCLUSIONS: CKD is associated with an increase in circulating angiogenesis and NO inhibitors, which impact proliferation and apoptosis of cardiac endothelial cells and promote EndMT, leading to cardiac fibrosis and capillary rarefaction. These processes may play key roles in CKD-associated CV disease.
BACKGROUND:Sudden cardiovascular death is increased in chronic kidney disease (CKD). Experimental CKD models suggest that angiogenesis and nitric oxide (NO) inhibitors induce myocardial fibrosis and microvascular dropout thereby facilitating arrhythmogenesis. We undertook this study to characterize associations of CKD with human myocardial pathology, NO-related circulating angiogenesis inhibitors, and endothelial cell behavior. METHODS: We compared heart (n=54) and serum (n=162) samples from individuals with and without CKD, and assessed effects of serum on human coronary artery endothelial cells (HCAECs) in vitro. Left ventricular fibrosis and capillary density were quantified in post-mortem samples. Endothelial to mesenchymal transition (EndMT) was assessed by immunostaining of post-mortem samples and RNA expression in heart tissue obtained during cardiac surgery. Circulating asymmetric dimethylarginine (ADMA), endostatin (END), angiopoietin-2 (ANG), and thrombospondin-2 (TSP) were measured, and the effect of these factors and of subject serum on proliferation, apoptosis, and EndMT of HCAEC was analyzed. RESULTS:Cardiac fibrosis increased 12% and 77% in stage 3-4 CKD and ESRD and microvascular density decreased 12% and 16% vs. preserved renal function. EndMT-derived fibroblast proportion was 17% higher in stage 3-4 CKD and ESRD (P trend = 0.02). ADMA, ANG, TSP, and END concentrations increased in CKD. Both individual factors and CKD serum increased HCAEC apoptosis (P=0.02), decreased proliferation (P=0.03), and induced EndMT. CONCLUSIONS: CKD is associated with an increase in circulating angiogenesis and NO inhibitors, which impact proliferation and apoptosis of cardiac endothelial cells and promote EndMT, leading to cardiac fibrosis and capillary rarefaction. These processes may play key roles in CKD-associated CV disease.
Authors: Charles A Herzog; Richard W Asinger; Alan K Berger; David M Charytan; Javier Díez; Robert G Hart; Kai-Uwe Eckardt; Bertram L Kasiske; Peter A McCullough; Rod S Passman; Stephanie S DeLoach; Patrick H Pun; Eberhard Ritz Journal: Kidney Int Date: 2011-07-13 Impact factor: 10.612
Authors: Susan MacLauchlan; Jun Yu; Marcus Parrish; Tara A Asoulin; Michael Schleicher; Marie M Krady; Jianmin Zeng; Paul L Huang; William C Sessa; Themis R Kyriakides Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Andrey Kazakov; Patrick Müller; Philippe Jagoda; Alexander Semenov; Michael Böhm; Ulrich Laufs Journal: Cardiovasc Res Date: 2011-11-21 Impact factor: 10.787
Authors: Sascha David; Philipp Kümpers; Alexander Lukasz; Danilo Fliser; Jens Martens-Lobenhoffer; Stefanie M Bode-Böger; Volker Kliem; Hermann Haller; Jan T Kielstein Journal: Nephrol Dial Transplant Date: 2010-02-22 Impact factor: 5.992
Authors: Sascha David; Stephen G John; Helen J Jefferies; Mhairi K Sigrist; Philipp Kümpers; Jan T Kielstein; Hermann Haller; Christopher W McIntyre Journal: Nephrol Dial Transplant Date: 2011-10-04 Impact factor: 5.992
Authors: Vineet Bhandari; Rayman Choo-Wing; Anantha Harijith; Huanxing Sun; Mansoor Ali Syed; Robert J Homer; Jack A Elias Journal: Am J Respir Cell Mol Biol Date: 2012-01-06 Impact factor: 6.914
Authors: Patrick H Pun; Thomas R Smarz; Emily F Honeycutt; Linda K Shaw; Sana M Al-Khatib; John P Middleton Journal: Kidney Int Date: 2009-06-17 Impact factor: 10.612
Authors: Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri Journal: Nat Med Date: 2007-07-29 Impact factor: 53.440
Authors: David M Charytan; Jonathan Himmelfarb; T Alp Ikizler; Dominic S Raj; Jesse Y Hsu; J Richard Landis; Amanda H Anderson; Adriana M Hung; Rajnish Mehrotra; Shailendra Sharma; Daniel E Weiner; Mark Williams; Marcelo DiCarli; Hicham Skali; Paul L Kimmel; Alan S Kliger; Laura M Dember Journal: Kidney Int Date: 2018-11-23 Impact factor: 10.612
Authors: David M Charytan; Hicham Skali; Nishant R Shah; Vikas Veeranna; Michael K Cheezum; Viviany R Taqueti; Takashi Kato; Courtney R Bibbo; Jon Hainer; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Kidney Int Date: 2017-10-13 Impact factor: 10.612
Authors: Nishant R Shah; David M Charytan; Venkatesh L Murthy; Hicham Skali Lami; Vikas Veeranna; Michael K Cheezum; Viviany R Taqueti; Takashi Kato; Courtney R Foster; Jon Hainer; Mariya Gaber; Josh Klein; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: J Am Soc Nephrol Date: 2015-10-12 Impact factor: 10.121
Authors: David M Charytan; Robert Foley; Peter A McCullough; John D Rogers; Peter Zimetbaum; Charles A Herzog; James A Tumlin Journal: Clin J Am Soc Nephrol Date: 2016-01-13 Impact factor: 8.237